Woodcock takes GMO to the next level

Share this article:
The FDA's director of drugs, Janet Woodcock, is pushing her manufacturing and product quality experts to “reinvigorate” her brainchild “GMPs (Good Manufacturing Practices) for 21st Century” initiative and move it to the next level.

“We've gotten a lot done on quality-by-design and our new review processes and so forth,” Woodcock said during a keynote address at an FDA/Temple University School of Pharmacy regulatory affairs conference.

“Industry is now stepping up to the plate, and we need to get to the next level, which would be to eliminate a lot of the manufacturing supplements because we have the appropriate quality-by-design information,” she said.

Last year at the Drug Information Association's annual meeting, FDA Office of New Drug Quality Assessment postmarketing evaluation division director Eric Duffy said the agency was developing categories of low-risk post-approval changes where less oversight might be appropriate. This effort was part of the agency's GMP initiative to develop a risk-based review paradigm to “downgrade” the filing categories for certain prior-approval supplements.

Also last year, the FDA held a public meeting on marketing application supplements where it received comments on how it could revise regulations to allow risk-based approaches based on manufacturing process understanding, and steps to reduce the number of supplements.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?